Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): A prospective, randomized, single-blind clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1783-1789

  Moleti, Mariacarla ^a   Violi, Maria Antonia ^a   Montanini, Daniela ^b   Trombetta, Costantino ^b   Di Bella, Beatrice ^a   Sturniolo, Giacomo ^a   Presti, Silvia ^a   Alibrandi, Angela ^c   Campenní, Alfredo ^d   Baldari, Sergio ^d   Trimarchi, Francesco ^a   Vermiglio, Francesco ^a  

^a Dipartimento di Medicina Clinica e Sperimentale Sezione di Endocrinologia   (Italy)

^b Dipartimento di Scienze Sperimentali Medico Chirurgiche Specialistiche Ed Odontostomatologiche Sezione di Oftalmologia   (Italy)

^c Dipartimento di Scienze Economiche   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; METHYLPREDNISOLONE ACETATE; RECOMBINANT THYROTROPIN;

ABLATION THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DETERIORATION; DISEASE SEVERITY; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THYROIDECTOMY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; THYROID GLAND; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME;

EID: 84899932089     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3093     Document Type: Article

References (20)

1. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves'ophthalmopathy. Thyroid. 2002;12:855-860.
2. Bartalena L. The dilemma of how to manage Graves'hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011;96:592-599.
3. Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves'hyperthyroidism associated with Graves'orbitopathy. Thyroid. 2011;21:279-283.
4. Moleti M, Mattina F, Salamone I, et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves'ophthalmopathy. Thyroid. 2003;13:653-658.
5. Menconi F, Marinò M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves'orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab. 2007;92:1653-1658.
6. Prummel MF, WiersingaWM,Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves'ophthalmopathy. Arch Intern Med. 1990;150: 1098-1101.
7. Daumerie C, Boschi A, Perros P. Is recombinant human TSH a trigger for Graves'orbitopathy Eur Thyroid J. 2012;1:105-109.
8. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11: 116-128.
9. European Group on Graves'Orbitopathy (EUGOGO); Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves'orbitopathy: The European Group on Graves'Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155:387-389.
10. Bartalena L, Baldeschi L, Dickins on A, et al; European Group on Graves'Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves'orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-285.
11. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves'ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9-14.
12. Bahn R. Graves'ophthalmopathy. N Engl J Med. 2010;362:726-738.
13. Hegedüs L, Bonnema SJ, Smith TJ, Brix TH. Treating the thyroid in the presence of Graves'ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:313-324.
14. Catz B, Perzik SL. Total thyroidectomy in the management of thyrotoxic and euthyroid Graves'disease. Am J Surg. 1969;118:434-439.
15. Werner SC, Feind CR, Aida M. Graves'disease and total thyroidectomy. Progression of severe eye changes and decrease in serum long acting thyroid stimulator after operation.NEngl J Med. 1967; 276:132-138.
16. De Groot LJ, Benjasuratwong Y. Evaluation of thyroid ablative therapy for ophthalmopathy of Graves'disease. Orbit. 1996;15: 187-196.
17. Leo M, Marcocci C, Pinchera A, et al. Outcome of Graves'orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab. 2012;97:E44-E48.
18. De Bellis A, Conzo G, Ce nnamo G, et al. Time course of Graves'ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine. 2012; 41:320-326.
19. Berg G, Anders son T, Sjödell L, Jansson S, Nyström E. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/ radioiodine and retinoic acid. Thyroid. 2005; 15:1389-1394.
20. Sturrock A, Stearns M, Pigott K, Wiersinga W, Vanderpump M. Recombinant thyrotropin to minimize the risk of deterioration in ophthalmopathy in a patient with papillary thyroid cancer. Thyroid. 2003;13:P69.